X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (2017 - 2025)

X4 Pharmaceuticals has reported Net Income towards Common Stockholders for 9 years, with the latest figure at -$23.9 million in Q4 2025.

• For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 39.92% year-over-year to -$23.9 million; the trailing twelve-month figure through Dec 2025 stood at -$79.2 million (down 111.48% YoY), and the FY2025 full-year result was -$79.2 million, down 111.2% from the prior year.
• Net Income towards Common Stockholders for Q4 2025 stood at -$23.9 million, up from -$29.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $90.8 million in Q2 2024, with the low at -$55.7 million in Q2 2023.
• Historically, Net Income towards Common Stockholders has averaged -$20.8 million across 5 years, with a median of -$24.1 million in 2022.
• The largest YoY upside for Net Income towards Common Stockholders was 263.04% in 2024 against a maximum downside of 1492.02% in 2024.
• X4 Pharmaceuticals' Net Income towards Common Stockholders stood at -$35.9 million in 2021, then increased by 18.96% to -$29.1 million in 2022, then surged by 34.27% to -$19.1 million in 2023, then sank by 108.16% to -$39.8 million in 2024, then surged by 39.92% to -$23.9 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$23.9 million (Q4 2025), -$29.8 million (Q3 2025), and -$25.7 million (Q2 2025), per Business Quant data.